Nintedanib and Azacitidine in Treating Participants With HOX Gene Overexpression Relapsed or Refractory Acute Myeloid Leukemia

NCT03513484 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

44

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukemia With t(9;11)(p22.3;q23.3); MLLT3-KMT2A
Fibroblast Growth Factor Basic Form Measurement
FLT3 Internal Tandem Duplication
Recurrent Adult Acute Myeloid Leukemia
Refractory Acute Myeloid Leukemia

Interventions

DRUG: Azacitidine
OTHER: Laboratory Biomarker Analysis
DRUG: Nintedanib

Sponsor

Northwestern University

Collaborators

[object Object]
[object Object]
[object Object]